ignificantly associated with increased odds of EAP.PURPOSE The aim of this study was to identify factors associated with failure of maxillary and mandibular dental implants before permanent crown placement. MATERIALS AND METHODS The present study included adults who underwent dental implantation between January 2003 and December 2016. Implant failure before the permanent prosthesis placement was defined as early implant failure. Patients were divided retrospectively into groups according to the status of their implants; ie, a group with no early implant failure and a group with at least one early failure. Patient-related and implant site-related factors were analysed. RESULTS 18 (4.8%) of the 376 patients had at least one implant that failed early. 49 (4.7%) of the 1,050 implants included in the study failed early. After adjustment, significant risk factors associated with early failure of maxillary implants included age, bone regeneration for insufficient bone, and signs of postoperative infection. In the mandibular implants, the only significant risk factor for early failure after adjustment was postoperative infection signs. CONCLUSIONS The risk factors associated with early implant failure differed between the maxilla and mandible. Early failure was more attributed to these causes than to a difference in morphology or bone quality between the maxilla and mandible. Prospective studies focusing on the interaction between these risk factors are needed.PURPOSE To compare the clinical and radiographic outcomes of platform switching (PS) and regular platform (RP) implants. MATERIALS AND METHODS This study was designed as a randomised controlled split-mouth trial. Eighteen patients, with bilaterally missing single premolars or molars to be restored with implant-supported single crowns, were consecutively enrolled. Implant sites were randomly assigned to be treated according to the PS concept (PS group), or with matching implant-abutment diameters (RP group). A total of 36 implants were placed in healed bone, with an insertion torque between 35 and 45 Ncm, according to a one-stage protocol. All the implants were loaded with a screw-retained provisional crown 3 months after implant insertion. Definitive screw-retained single crowns were delivered 2 months later. Outcome measures were implant and prosthetic survival rates, biological and prosthetic complications, marginal bone level (MBL) changes, pocket probing depth (PPD) and bleeding on probing (BOP). Clinicalnd 1.06 ± 0.24 mm (95% CI 0.94 to 1.17) in the PS group, with no statistically significant difference between groups (P = 0.70). Sixty months after loading the mean MBL was 1.24 ± 0.39 mm (95% CI 1.05 to 1.43) in the RP group and 1.20 ± 0.21 mm (95% CI 1.01 to 1.39) in the PS group, with no statistically significant difference between the groups (P = 0.85). The mean PPD was 2.58 ± 0.58 mm (95% CI 2.32 to 2.84) in the RP group and 2.40 ± 0.72 mm (95% CI 2.21 to 2.59) in the PS group at 60 months follow-up, with no statistically significant difference between the groups (P = 0.49). The mean BOP was 0.90 ± 0.88 (95% CI 0.58 to 1.22) in the RP group and 0.93 ± 0.97 (95% CI 0.51 to 1.35) in the PS group at 60 months of follow-up, with no statistically significant difference between the groups (P = 0.85). CONCLUSIONS Implants restored according to the PS concept and matching implant-abutment diameters showed comparable clinical and radiographic results up to 5 years after loading.PURPOSE To assess the technical and biological complications of screw- and cement-retained implant-supported full-arch dental prostheses. MATERIALS AND METHODS An electronic search was conducted on Medline/PubMed and Cochrane databases in February 2019; irrespective of any time restrictions using MeSH terms. All studies were first reviewed by abstract and subsequently by full-text reading. Further hand search was performed to identify other related references. Articles only related to cement-retained and/or screw-retained reconstructions in full-arch fixed dental prostheses (FDP) were included. RESULTS The initial literature search resulted in 3670 papers. 3478 articles remained after removing duplicate articles, and 3439 articles were further excluded by the reviewers after the abstract screening, which resulted in a selection of 39 studies. 12 studies were further excluded due to not fulfilling the inclusion criteria. Hand searching resulted in two additional papers being included, and finally, 29 articles were included in this review. Screw-retained full-arch fixed dental prostheses have fewer complications than cemented reconstructions. Biological complications such as marginal bone loss > 2 mm occurred more frequently in cemented reconstructions, and technical complications such as screw-loosening and screw fracture occurred more in screw-retained reconstructions. CONCLUSION Cemented reconstructions exhibited more biological complications (implant loss, bone loss > 2 mm) and screw-retained prostheses exhibited more technical problems. Clinical outcomes were influenced by both fixations in different ways. The screw-retained restorations were more easily retrievable than cemented ones, therefore, technical and eventually biological complications could be treated more easily. For this reason, and for their higher biological compatibility, these reconstructions are preferable.BACKGROUND Doxorubicin-induced myocardial toxicity is associated with oxidative stress, cardiomyocyte, apoptosis, and loss of contractile function. Previous studies showed that microRNA-375 (miR-375) expression was increased in mouse models of heart failure and clinically, and that inhibition of miR-375 reduced inflammation and increased survival of cardiomyocytes. This study aimed to investigate the effects and mechanisms of inhibition of miR-375 in a mouse model of doxorubicin-induced cardiac toxicity in vivo and in doxorubicin-treated rat and mouse cardiomyocytes in vitro. MATERIAL AND METHODS The mouse model of doxorubicin-induced cardiac toxicity was developed using an intraperitoneal injection of doxorubicin (15 mg/kg diluted in 0.9% saline) for eight days. Treatment was followed by a single subcutaneous injection of miR-375 inhibitor. click here H9c2 rat cardiac myocytes and adult murine cardiomyocytes (AMCs) were cultured in vitro and treated with doxorubicin, with and without pretreatment with miR-375 inhibitor.